Genenta Science S P A 's ROA from the fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Genenta Science S P A 's ROA in the fourth quarter of 2025?
Genenta Science S P A recorded a cumulative net loss of $-7 million during 12 months ending in the fourth quarter of 2025, resulting in a negative return on assets (ROA) of -20.48%.

However, within the Healthcare sector 425 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2025 from to 4072.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Dec 31 2025) IV. Quarter	0 III. Quarter	0 II. Quarter	0 I. Quarter	(Dec 31 2024) IV. Quarter
Y / Y Total Assets Change	115.12 %	115.12 %	115.12 %	115.12 %	-33.66 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-7	-10	-10	-10	-10
Return On Assets (TTM)	-20.48 %	-32.26 %	-38.16 %	-46.69 %	-60.12 %
GNTA's Total Ranking	# 4072	#	#	#	# 4928
Total Assets (TTM) in million	36	36	36	36	17
Seq. Total Assets Change	0 %	0 %	0 %	115.12 %	0 %
Seq. Net Income Change	-	-	-	-	-

GNTA's 5 Years Annual ROA >> Back to GNTA Management Effectiveness >> Compare GNTA ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 46
Sector	# 426
Overall	# 4036

Return On Assets Statistics
High	Average	Low
-20.48 %	-39.52 %	-60.12 %
(Dec 31 2025)		(Dec 31 2024)

Financial Statements
Genenta Science S P A 's Assets	$ 36 million	GNTA's Balance sheet
Genenta Science S P A 's Income	$ -7 million	Quarterly GNTA's Income Statement
GNTA's Income by Division		See GNTA's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	115.12 %	-33.66 %	-33.17 %	31.74 %	-
Total Assets in million	36	17	25	37	28
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-7	-10	-13	-9	-6
Annual Return On Assets	-20.48 %	-60.12 %	-52.11 %	-25.35 %	-21.78 %

GNTA's 5 Years Annual ROA >> Back to GNTA Management Effectiveness >> Compare GNTA ROA to its Competitors

More Return On Assets Ratios
GNTA's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
GNTA's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for GNTA's Competitors
Subscribers only: Roa for Genenta Science S P A 's Suppliers
Subscribers only: Return On Assets for GNTA's Customers

You may also want to know
GNTA's Roi	GNTA's Inventory Turnover Ratio	GNTA's Growth Rates	GNTA's Dividend Comparisons
	GNTA's Profitability Ratios	GNTA's Asset Turnover Ratio	GNTA's Dividend Growth
GNTA's Roe	GNTA's Valuation Ratios	GNTA's Financial Strength Ratios	GNTA's Dividend Payout Ratio

Companies with similar Return On Assets at Dec 31 2025, within Healthcare Sector

ROA

Date modified: 2026-07-07T11:25:41+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.